OakChart

CytoMed Therapeutics Ltd

GDTCHealthcare·Biotechnology·Singapore·Nano·NASD·Nov 10 • 3:59 PM ET

0.83590.0000 (0.00%)
2026-11-11 15:29 CET
Market cap
9.89 USD m
Revenue, TTM
0.25 USD m
Net income, TTM
-2.73 USD m
Free cash flow, TTM
-3.27 USD m
EPS diluted, TTM
-0.23
P/E
-
Compare

Price

GDTC against its 20, 50 and 200-day averages
2050200
0.801.001.201.401.601.6M3.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GDTCclose 0.8420-day 0.8950-day 0.89200-day 0.970.84

73.0% under 3.10 on 6 Nov 2025. Last 15 sessions, 17.6% high to low

Profile

GDTC
52-week range, 10% of the way up
0.682.29

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

Employees42
IPOApr 14, 2023
Beta0.06
ATR, 14d0.09
Rel volume0.00
Short float0.34%
Insider own56.10%
Inst own0.27%

Snapshot

6 groups

Valuation

Index-
Market Cap9.89M
Enterprise Value9.44M
Income-2.73M
Sales0.25M
Book/sh0.32
Cash/sh0.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees42
IPOApr 14, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S39.56
P/B2.59
P/C8.75
P/FCF-
EV/EBITDA-
EV/Sales37.76
Quick Ratio2.64
Current Ratio2.64
Debt/Eq0.09
LT Debt/Eq0.08
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.23
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-8.01% -226.97%
Sales past 3/5Y- -
EPS Y/Y TTM3.91%
Sales Y/Y TTM49.09%
EPS Q/Q20.63%
Sales Q/Q4.53%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own56.10%
Insider Trans1.72%
Inst Own0.27%
Inst Trans5.43%
ROA-45.59%
ROE-57.78%
ROIC-65.87%
Gross Margin-286.22%
Oper. Margin-1339.92%
Profit Margin-1076.73%
SMA20-6.10%
SMA50-6.30%
SMA200-14.25%
Trades-

Technical

Shs Outstand11.93M
Shs Float5.20M
Short Float0.34%
Short Ratio1.00
Short Interest0.02M
52W High2.29 -63.50%
52W Low0.68 22.91%
Volatility6.95% 9.43%
ATR (14)0.09
RSI (14)41.10
Beta0.06
Rel Volume0.00
Avg Volume17.64K
Volume0

Performance

Perf Week-8.14%
Perf Month3.02%
Perf Quarter3.39%
Perf Half Y8.64%
Perf YTD-37.39%
Perf Year-57.57%
Perf 3Y-79.30%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price4.16
Prev Close0.84
Price0.84
Change %0.00%

Peers

Mkt cap
TickerCompanyMkt cap
INABIN8bio Inc9.73M
ACETAdicet Bio Inc28.30M
INKTMiNK Therapeutics Inc51.08M
NKTXNkarta Inc108.27M
IPSCCentury Therapeutics Inc304.21M
SNTISenti Biosciences Holdings Inc4.33M
FATEFate Therapeutics Inc217.61M
CELUCelularity Inc23.07M
GTBPGT Biopharma Inc8.16M
ERNAErnexa Therapeutics Inc3.74M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
mDR Ltd10% OwnerAug 11 '26Proposed Sale0.88117,337103,257Aug 11 10:37 AM
Choo Chee KongDirectorMay 13 '26Buy1.15112,000128,778430,324Jun 15 06:15 AM
mDR LTD10% OwnerMay 13 '26Proposed Sale0.84117,33798,094May 13 10:03 AM
mDR LTD10% OwnerFeb 12 '26Proposed Sale1.04117,337122,030Feb 12 09:03 AM

News

latest 14 of 112
  • CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) -5.81% -8.83%
  • Cytomed Therapeutics refutes misleading claims, reaffirms clinical progress (TipRanks)
  • CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress (GlobeNewswire)
  • CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital (GlobeNewswire)
  • CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia (GlobeNewswire)
  • Loading…
  • CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India (GlobeNewswire)
  • CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy (GlobeNewswire)
  • CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% (GlobeNewswire)
  • Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
  • CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets (GlobeNewswire) +16.58%
  • CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic ?d T Cells in Acute Myeloid Leukemia (GlobeNewswire)
  • Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition (GlobeNewswire)
  • CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024S12024-09-30-0.070-----
2024Q12024-05-29-0.040-0.050-0.0400.130.131
2023S12023-11-17-0.220--0.140---
2023Q12023-07-20-0.060--0.0600.13--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-0.260-0.260-0.2900.430.43
2024FY-0.160--50.87-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025FYS2025-01-161000.520.520.52
2025FYS2025-01-151000.520.520.52
2025FYS2025-01-141000.520.520.52
2025FYS2025-01-131000.520.520.52
2025FYS2025-01-121000.520.520.52
2025FYS2025-01-111000.520.520.52
2025FYS2025-01-101000.520.520.52
2025FYS2025-01-091000.520.520.52
2025FYS2025-01-081000.520.520.52
2025FYS2025-01-071000.520.520.52
2025FYS2025-01-061000.520.520.52
2025FYS2025-01-051000.520.520.52
2025FYS2025-01-041000.520.520.52
2025FYS2025-01-031000.520.520.52

Estimate history

EPS, annual-0.001-0.001-0.208-0.29-0.163-0.262
Period202020212022202320242025
EPS, quarterly
Period
Sales, annual00000.0520.248
Period202020212022202320242025
Sales, quarterly
Period
Shares, annual2314.8152848.51210.9411.52911.5411.828
Period202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.250.250.050.000.000.000.00
Cost of Goods Sold Incl. D&A0.980.940.570.080.080.080.06
Gross Profit-0.73-0.69-0.52-0.08-0.08-0.08-0.06
Selling, General and Administrative Excl. Other2.672.822.103.121.611.320.94
Research and Development1.681.701.431.181.100.810.75
Other Operating Expense0.010.010.010.000.010.000.00
Operating Income-3.40-3.52-2.63-3.20-1.70-1.40-1.00
Interest Expense0.020.020.020.040.090.090.08
Unusual Expense0.050.17-0.040.290.79-0.020.37
Net Income Before Taxes-2.76-3.05-1.90-3.05-2.25-1.37-1.40
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-2.76-3.06-1.89-3.08-2.27-1.53-1.40
Net Income From Continuing Operations-2.73-3.05-1.88-3.08-2.27-1.53-1.40
Net Income-2.73-3.05-1.88-3.08-2.27-1.53-1.40
EPS (Recurring)-0.23-0.25-0.17-0.27-0.16-0.00-0.00
EPS (Basic, Before Extraordinaries)-0.23-0.26-0.16-0.29-0.21-0.00-0.00
EPS (Diluted)-0.23-0.26-0.16-0.29-0.21-0.00-0.00
EBITDA-3.19-3.34-2.53-3.12-1.62-1.32-0.94
Non-Operating Income (Expense)0.710.640.710.470.330.100.05
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.20-----
Price To Sales Ratio48.2362.63754.44----
Gross Margin-286.22-277.74-991.85----
Operating Margin-1,339.92-1,415.96-5,049.74----
Net Margin-1,076.73-1,227.07-3,621.08----
Shares Outstanding11.9311.8311.5411.5310.942,848.512,314.81
Market Capitalization9.899.8939.2456.4956.49--

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue0.120.130.120.050.000.000.000.00
Cost of Goods Sold Incl. D&A0.420.560.38-0.120.040.150.04
Gross Profit-0.29-0.43-0.26--0.12-0.04-0.15-0.04
Selling, General and Administrative Excl. Other1.271.401.471.281.271.481.010.98
Research and Development0.860.820.880.710.630.580.490.66
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.57-1.83-1.73-1.23-1.39-1.52-1.16-1.03
Interest Expense0.010.010.010.010.010.010.030.05
Unusual Expense0.030.020.100.07-0.110.100.700.68
Net Income Before Taxes-1.40-1.36-1.69-1.08-0.82-1.45-1.60-1.52
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.40-1.36-1.70-1.08-0.81-1.46-1.62-1.53
Net Income From Continuing Operations-1.39-1.35-1.69-1.08-0.81-1.46-1.61-1.53
Net Income-1.39-1.35-1.69-1.08-0.81-1.46-1.61-1.53
EPS (Recurring)-0.11-0.11-0.14-0.09-0.08-0.12-0.10-0.10
EPS (Basic, Before Extraordinaries)-0.12-0.11-0.15-0.09-0.07-0.13-0.14-0.14
EPS (Diluted)-0.12-0.11-0.15-0.09-0.07-0.13-0.14-0.14
EBITDA-1.46-1.73-1.66-1.10-1.27-1.48-1.01-0.99
Non-Operating Income (Expense)0.200.500.150.230.470.170.300.23
Stock Option Compensation Expense0.01-0.28-----
Price To Sales Ratio48.2363.36152.58748.56----
Gross Margin-238.85-330.85-220.34-----
Operating Margin-1,272.93-1,403.05-1,469.39-2,348.65----
Net Margin-1,125.61-1,030.68-1,439.35-2,055.08----
Shares Outstanding11.9311.8311.5411.5411.5411.5311.5310.94
Market Capitalization9.8915.6628.2439.2424.0056.4933.3733.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments1.633.646.821.181.860.67
Short Term Receivables0.130.110.200.050.020.23
Inventories0.000.000.000.000.000.00
Other Current Assets1.090.640.640.630.560.21
Total Current Assets2.854.407.651.862.431.11
Net Property, Plant & Equipment2.872.381.571.851.851.74
Total Investments and Advances0.010.160.150.180.200.00
Long-Term Note Receivable0.380.370.00---
Intangible Assets0.100.070.010.010.020.03
Other Assets0.000.000.000.000.000.00
Total Assets6.217.389.383.904.512.89
Short Term Debt Incl. Current Port. of LT Debt0.050.030.032.792.011.79
Accounts Payable0.100.030.020.010.030.01
Income Tax Payable--0.000.00--
Other Current Liabilities0.410.380.490.300.140.26
Total Current Liabilities0.550.440.543.112.182.06
Long Term Debt0.330.310.310.350.410.46
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.880.750.853.462.592.53
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.096.578.520.441.920.36
Total Shareholders Equity5.096.578.520.441.920.36
Accumulated Minority Interest0.240.06-0.00-0.00-0.00-0.00
Total Equity5.336.638.520.441.920.36
Total Liabilities & Stockholders Equity6.217.389.383.904.512.89
Book Value Per Share0.430.570.740.040.000.00
Tangible Book Value Per Share0.420.560.740.040.000.00
Full-Time Employees4243342824-
Price to Book Ratio2.595.235.815.81--
Return on Assets-44.84-22.48-46.36-54.00-41.27-
Return on Equity-52.25-24.95-68.66-192.40-133.76-
Return on Invested Capital-56.24-27.38-34.83-286.62-65.41-170.10
Quick Ratio5.179.8914.080.601.120.54
Current Ratio5.179.8914.080.601.120.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-2.81-3.06-1.89-3.08-2.27-1.53-1.40
Depreciation0.360.310.250.280.280.250.21
Other Funds (Non Cash)-0.110.40-0.010.120.800.190.42
Funds from Operations-2.55-2.35-1.65-2.67-1.18-1.09-0.78
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-0.33-0.37-0.050.080.08-0.270.08
Cash from Operating Activities-2.89-2.72-1.69-2.59-1.10-1.36-0.69
Capital Expenditures-0.43-0.54-1.12-0.04-0.34-0.43-0.19
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.800.540.120.000.000.000.00
Purchase or Sale of Investments0.400.591.87-2.060.00-0.18-0.18
Purchase of Investments-0.02-0.040.00-2.060.00-0.18-0.18
Sale Or Maturity of Investments0.430.631.870.000.000.000.00
Other Uses0.000.00-0.370.000.000.000.00
Other Sources0.160.000.000.000.000.000.00
Cash from Investing Activities0.930.590.49-2.11-0.34-0.61-0.37
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock0.220.220.008.421.102.980.36
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock0.220.220.008.421.102.980.36
Proceedsfrom Stock Options0.220.220.008.421.102.980.36
Issuance or Reduction of Debt, Net-0.05-0.03-0.03-0.25-0.310.221.08
Change in Long Term Debt---0.00-0.000.00
Issuance of Long Term Debt---0.00-0.000.00
Reduction of Long Term Debt---0.00-0.000.00
Net Financing Active Other Cash Flow0.550.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities0.720.18-0.038.160.793.191.44
Exchange Rate Effect0.11-0.030.09-0.01-0.02-0.01-0.00
Net Change in Cash-1.12-1.99-1.143.46-0.681.210.37
Free Cash Flow-3.27-3.21-2.74-2.63-1.45-1.80-0.87
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments1.131.632.243.644.786.82
Short Term Receivables0.320.130.160.110.300.20
Inventories0.000.000.000.000.000.00
Other Current Assets1.051.090.810.640.620.64
Total Current Assets2.502.853.214.405.697.65
Net Property, Plant & Equipment2.822.872.732.381.831.57
Total Investments and Advances0.010.010.180.160.160.15
Intangible Assets0.080.100.060.070.010.01
Other Assets0.000.000.000.000.000.00
Total Assets5.426.216.567.388.059.38
Short Term Debt Incl. Current Port. of LT Debt0.050.050.050.030.030.03
Accounts Payable0.020.100.060.030.030.02
Income Tax Payable-----0.00
Other Current Liabilities0.880.410.440.380.200.49
Total Current Liabilities0.950.550.550.440.260.54
Long Term Debt0.300.330.340.310.290.31
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.250.880.890.750.550.85
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.845.095.616.577.508.52
Total Shareholders Equity3.845.095.616.577.508.52
Accumulated Minority Interest0.330.240.060.06-0.00-0.00
Total Equity4.175.335.676.637.508.52
Total Liabilities & Stockholders Equity5.426.216.567.388.059.38
Book Value Per Share0.320.430.490.570.650.74
Tangible Book Value Per Share0.320.420.480.560.650.74
Price to Book Ratio2.592.753.955.232.815.81
Return on Assets-45.59-44.76-37.94-22.50-24.77-46.37
Return on Equity-57.78-52.16-42.29-24.97-26.36-68.68
Return on Invested Capital-33.41-24.85-28.49-15.66-10.38-16.56
Quick Ratio2.645.175.819.8921.5314.08
Current Ratio2.645.175.819.8921.5314.08

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-1.40-1.40-1.70-1.09-0.81-1.45
Depreciation0.190.180.140.130.120.13
Other Funds (Non Cash)0.01-0.120.530.04-0.050.02
Funds from Operations-1.20-1.35-1.03-0.92-0.74-1.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.09-0.25-0.130.08-0.130.28
Cash from Operating Activities-1.29-1.59-1.16-0.84-0.87-1.03
Capital Expenditures-0.15-0.28-0.26-0.70-0.43-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.260.540.000.120.000.00
Purchase or Sale of Investments0.000.400.192.24-0.350.00
Purchase of Investments0.00-0.02-0.010.35-0.350.00
Sale Or Maturity of Investments0.000.430.211.880.000.00
Other Uses0.000.000.000.24-0.62-2.05
Other Sources0.160.000.000.000.000.00
Cash from Investing Activities0.270.66-0.071.90-1.40-2.08
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.220.000.000.00-0.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.220.000.000.00-0.09
Proceedsfrom Stock Options0.000.220.000.000.00-0.09
Issuance or Reduction of Debt, Net-0.02-0.02-0.01-0.01-0.010.01
Net Financing Active Other Cash Flow0.550.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.530.20-0.02-0.02-0.01-0.08
Exchange Rate Effect0.000.11-0.140.040.05-0.00
Net Change in Cash-0.50-0.63-1.391.08-2.23-3.19
Free Cash Flow-1.44-1.83-1.43-1.47-1.30-1.06

Revenue breakdown

Pharmaceutical Preparations2024: 52.02K 2025: 248.21K
Singapore2024: 52.02K 2025: 248.21K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.34%0.0M5.2M19.94K
2026-10-150.37%0.0M5.2M80.82K
2026-09-300.33%0.0M5.2M79.23K
2026-09-150.07%0.0M5.2M81.10K
2026-08-310.12%0.0M5.2M79.95K
2026-08-140.08%0.0M5.2M83.25K
2026-07-310.11%0.0M5.2M81.85K
2026-07-150.48%0.0M6.3M19.21K
2026-06-300.60%0.0M6.3M18.57K
2026-06-150.73%0.0M6.3M17.36K
2026-05-291.07%0.1M6.4M15.13K
2026-05-151.11%0.1M6.4M15.56K
2026-04-301.47%0.1M4.6M562.58K
2026-04-151.55%0.1M4.6M575.38K
2026-03-312.03%0.1M4.1M581.72K
2026-03-132.90%0.1M4.0M585.47K
2026-02-273.40%0.1M4.0M583.20K
2026-02-134.89%0.2M4.0M594.73K
2026-01-300.35%0.0M4.0M70.18K
2026-01-150.66%0.0M4.0M99.02K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-23SCHEDULE 13G/ASEC
2026-10-16SCHEDULE 13D/ASEC
2026-10-13SCHEDULE 13D/ASEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-09SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-07-244/A2026-07-14SEC
2026-07-24SCHEDULE 13D/ASEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-03SEC
2026-05-263Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-153Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-153Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-153Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-153Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-153Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-15SEC
2026-05-13144Filing for proposed sale of securities under Rule 144.SEC
2026-05-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-11SEC
2026-04-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-03-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-03-3120-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-02-12144Filing for proposed sale of securities under Rule 144.SEC
2026-01-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-28SEC
2026-01-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-13SEC
2025-12-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-08SEC
2025-11-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-18SEC
2025-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05128.78K100
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
UBS Group AG0.33%
StoneX Group Inc.0.23%
Axiom Investment Management LLC0.06%
OSAIC HOLDINGS, INC.0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.04%

OakChart. GDTC. Cached 15 minutes.

Some panels did not load: ratings.